Suppr超能文献

血液透析中的抗凝治疗:一篇叙述性综述。

Anticoagulation in hemodialysis: A narrative review.

机构信息

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Department of Internal Medicine, Boston Medical Center, Boston, MA, USA.

出版信息

Semin Dial. 2021 Mar;34(2):103-115. doi: 10.1111/sdi.12932. Epub 2020 Nov 1.

Abstract

Systemic anticoagulation in maintenance hemodialysis (HD) has historically been considered necessary to maintain the extracorporeal circuit (ECC) and preserve dialysis efficiency. Unfractionated heparin (UFH) is the most commonly used anticoagulant due to low cost and staff familiarity. Despite widespread use, there is little standardization of heparin dosing protocols in the United States. Although the complication rates with UFH are low for the general population, certain contraindications have led to exploration in alternative anticoagulants in patients with end-stage kidney disease (ESKD). Here we review the current evidence regarding heparin dosing protocols, complications associated with heparin use, and discuss alternatives to UFH including anticoagulant-free routine HD.

摘要

在维持性血液透析 (HD) 中,全身抗凝在历史上被认为是维持体外循环 (ECC) 和保持透析效率所必需的。由于成本低且工作人员熟悉,未分级肝素 (UFH) 是最常用的抗凝剂。尽管广泛使用,但美国肝素给药方案几乎没有标准化。尽管 UFH 对普通人群的并发症发生率较低,但某些禁忌症导致人们探索终末期肾病 (ESKD) 患者的替代抗凝剂。在这里,我们回顾了关于肝素给药方案、肝素使用相关并发症的现有证据,并讨论了 UFH 的替代方法,包括无抗凝剂常规 HD。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验